Bionpharma, Inc.

NEW YORK, Sept. 23, 2022 /PRNewswire/ -- One of the key trends in the progesterone market is the rise in research and development of progesterone drugs. Various players are expanding their research to develop new formulations of the existing female infertility drugs due to the significant unmet demand. For instance, MVT-602 targets the kisspeptin system to stimulate reproductive hormones. It can effectively treat many reproductive disorders such as PCOS and hypothalamic amenorrhea (HA). Continue Reading Technavio has announced its latest market research report titled Global Progesterone Market 2022-2026 The progesterone market size is expected to grow by USD 1.23 billion. In addition, the growth momentum of the market will accelerate at a CAGR of 12.96% during the forecast period, according to Technavio. Get a comprehensive report summary describing the market size and forecast along with research methodology. The FREE sample report is available in PDF format The increasing prevalence of breast cancer is driving the progesterone market growth. However, factors such as stringent regulations may challenge the market growth during the forecast period. Progesterone Market: Type Landscape By type, the market has been segmented into synthetic progesterone and natural progesterone. The synthetic progesterone segment will be the largest contributor to market growth during the forecast period. Synthetic progesterone drugs help regulate the monthly menstrual cycle. Therefore, the advantages of synthetic progesterone will accelerate the market growth during the forecast period. Progesterone Market: Geographic Landscape By geography, the market has been segmented into North America, Europe, Asia, and Rest of World (ROW). North America is going to have lucrative growth during the forecast period. About 43% of the market's overall growth is expected to originate from North America. The US and Canada are the key countries for the progesterone market in North America. The growth of the region is attributed to factors such as the rising prevalence of kidney, breast, or uterine cancer types and the rising population of menopausal women. Some Key Companies and their Offerings AbbVie Inc., Alkem Laboratories Ltd., Aquatic Group, Bionpharma Inc., Blubell Pharma Group, Cadila Pharmaceuticals Ltd., Caesar and Loretz GmbH, Cipla Ltd., Dr. Reddys Laboratories Ltd., Estrellas Life Sciences Pvt. Ltd., Fagron NV, Glenmark Pharmaceuticals Ltd, Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Kiama Lifesciences, Lupin Ltd., Organon and Co., PROCAPS S.A, Teva Pharmaceutical Industries Ltd., Virtus Pharmaceuticals LLC, among others, are the main players in the market. The key offerings of some of these vendors are listed below: Alkem Laboratories Ltd. - The company offers ULTIGEST SR 200MG TAB as medication for a hormone prescribed for replacement therapy in women who have passed menopause. Aquatic Group - The company offers injection I.P Luteum Depot as progesterone drugs. Bionpharma Inc. - The company manufactures progesterone drugs. Blubell Pharma Group - The company offers BELGEST 500 and BELGEST N under the injection section as progesterone. Cadila Pharmaceuticals Ltd. - The company offers ALGEST SR 400MG tab as progesterone drugs, which are made using milk-making glands to help in the menstrual cycle. This report provides a full list of key vendors, their strategies, and the latest developments. Request a FREE PDF Sample Now What our Reports Offer Market share assessments for the regional-level and country-level segments Strategic recommendations for the new entrants Covers market data for 2021, 2022, until 2026 Market trends (opportunities, drivers, threats, challenges, investment opportunities, and recommendations) Strategic recommendations in key business segments based on the market estimations Competitive landscaping mapping the key common trends Company profiling with financials, detailed strategies, and recent developments Supply chain trends mapping the latest technological advancements Related Reports Women's Health Therapeutics Market by Type and Geography - Forecast and Analysis 2022-2026: The women's health therapeutics market share is expected to increase by USD 30.35 billion from 2021 to 2026. Stem Cell Umbilical Cord Blood (UCB) Market by End-user and Geography - Forecast and Analysis 2022-2026: The stem cell umbilical cord blood (UCB) market share is expected to increase by USD 1.47 bn from 2021 to 2026. Browse Health Care Market Reports Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Type 5.1 Market segments Exhibit 24: Chart on Type - Market share 2021-2026 (%) Exhibit 25: Data Table on Type - Market share 2021-2026 (%) 5.2 Comparison by Type Exhibit 26: Chart on Comparison by Type Exhibit 27: Data Table on Comparison by Type 5.3 Synthetic progesterone - Market size and forecast 2021-2026 Exhibit 28: Chart on Synthetic progesterone - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Synthetic progesterone - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Synthetic progesterone - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Synthetic progesterone - Year-over-year growth 2021-2026 (%) 5.4 Natural progesterone - Market size and forecast 2021-2026 Exhibit 32: Chart on Natural progesterone - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Natural progesterone - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Natural progesterone - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Natural progesterone - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Type Exhibit 36: Market opportunity by Type ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Germany - Market size and forecast 2021-2026 Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.9 UK - Market size and forecast 2021-2026 Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.10 Canada - Market size and forecast 2021-2026 Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.11 France - Market size and forecast 2021-2026 Exhibit 74: Chart on France - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on France - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on France - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on France - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 78: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 79: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 80: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 81: Overview on factors of disruption 9.4 Industry risks Exhibit 82: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 83: Vendors covered 10.2 Market positioning of vendors Exhibit 84: Matrix on vendor position and classification 10.3 Alkem Laboratories Ltd. Exhibit 85: Alkem Laboratories Ltd. - Overview Exhibit 86: Alkem Laboratories Ltd. - Business segments Exhibit 87: Alkem Laboratories Ltd. - Key news Exhibit 88: Alkem Laboratories Ltd. - Key offerings Exhibit 89: Alkem Laboratories Ltd. - Segment focus 10.4 Aquatic Group Exhibit 90: Aquatic Group - Overview Exhibit 91: Aquatic Group - Product / Service Exhibit 92: Aquatic Group - Key offerings 10.5 Bionpharma Inc. Exhibit 93: Bionpharma Inc. - Overview Exhibit 94: Bionpharma Inc. - Product / Service Exhibit 95: Bionpharma Inc. - Key offerings 10.6 Blubell Pharma Group Exhibit 96: Blubell Pharma Group - Overview Exhibit 97: Blubell Pharma Group - Product / Service Exhibit 98: Blubell Pharma Group - Key offerings 10.7 Cadila Pharmaceuticals Ltd. Exhibit 99: Cadila Pharmaceuticals Ltd. - Overview Exhibit 100: Cadila Pharmaceuticals Ltd. - Business segments Exhibit 101: Cadila Pharmaceuticals Ltd. - Key offerings Exhibit 102: Cadila Pharmaceuticals Ltd. - Segment focus 10.8 Estrellas Life Sciences Pvt. Ltd. Exhibit 103: Estrellas Life Sciences Pvt. Ltd. - Overview Exhibit 104: Estrellas Life Sciences Pvt. Ltd. - Product / Service Exhibit 105: Estrellas Life Sciences Pvt. Ltd. - Key offerings 10.9 Intas Pharmaceuticals Ltd. Exhibit 106: Intas Pharmaceuticals Ltd. - Overview Exhibit 107: Intas Pharmaceuticals Ltd. - Product / Service Exhibit 108: Intas Pharmaceuticals Ltd. - Key offerings 10.10 PROCAPS S.A Exhibit 109: PROCAPS S.A - Overview Exhibit 110: PROCAPS S.A - Product / Service Exhibit 111: PROCAPS S.A - Key offerings 10.11 Teva Pharmaceutical Industries Ltd. Exhibit 112: Teva Pharmaceutical Industries Ltd. - Overview Exhibit 113: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key news Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 116: Teva Pharmaceutical Industries Ltd. - Segment focus 10.12 Virtus Pharmaceuticals LLC Exhibit 117: Virtus Pharmaceuticals LLC - Overview Exhibit 118: Virtus Pharmaceuticals LLC - Product / Service Exhibit 119: Virtus Pharmaceuticals LLC - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 120: Inclusions checklist Exhibit 121: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 122: Currency conversion rates for US$ 11.4 Research methodology Exhibit 123: Research methodology Exhibit 124: Validation techniques employed for market sizing Exhibit 125: Information sources 11.5 List of abbreviations Exhibit 126: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Signet Healthcare Partners and Bionpharma Inc today announced the sale of CoreRx, a global contract development and manufacturing organization ("CDMO"). Following the sale to private equity firm NovaQuest Private Equity, Signet Healthcare Partners will retain a meaningful equity stake in CoreRx. The terms of the transaction are not disclosed. Based in Clearwater, FL, CoreRx is a leading provider of clinical and commercial CDMO services to a wide range of small to mid-sized pharmaceutical and biotech clients. Founded in 2006, the Company offers preformulation, formulation, analytical and stability, clinical manufacturing, commercial manufacturing and packaging service. Signet invested in CoreRx in 2015 and Bionpharma, a Signet portfolio company, became a shareholder in 2017. During the past five years, Signet has worked alongside management to build deep development expertise that allows it to solve complex formulation challenges. During this period, CoreRx has evolved from earlier stage projects into becoming a reliable producer of commercial products. CoreRx has expanded its range of formulation capabilities which will provide a platform for future growth. As a result, CoreRx’s revenues and profits have significantly grown during this five-year period. James Gale, a Managing Director of Signet Heathcare Partners states: "We want to express our appreciation to Todd Daviau and the CoreRx management team who have built the Company into one of the leading CDMOs in the US. It has been rewarding to see the Company develop products that are now being used to improve the lives of patients. We believe the Company has a bright future and we look forward to continuing as a shareholder." Todd Daviau, Chief Executive Officer of CoreRx, Inc. adds: "It has been a pleasure working with Signet and Bionpharma as we have built our Company from a small development organization into a high-quality, end-to-end CDMO. The Signet team has offered substantial operational value during their investment tenure and has been a true partner. We look forward to their continued involvement as a shareholder." Venkat Krishnan, Chief Executive Officer of Bionpharma Inc adds: "We are grateful to Todd and the management team of CoreRx for a superb job in building value for us, both as a shareholder and a client. We have worked together on bringing a number of products through the approval process. We have found them to be a responsive development partner and a reliable supplier of product." William Blair & Company served as exclusive financial advisor to CoreRx. Sheppard Mullin and Johnson Pope served as legal advisors to CoreRx. About CoreRx CoreRx is a CDMO with full-service capabilities to support clinical through commercial manufacturing, offering state of the art facilities to support your supply chain needs. Our integrated offerings provide comprehensive services for the development, manufacturing, and testing of solid, liquid, and semi-solid dosage forms. For more information, please visit . About Signet Healthcare Partners Signet Healthcare Partners is an established provider of growth capital to innovative healthcare companies. Signet invests in commercial-stage healthcare companies that are revenue generating or preparing for commercial launch. The firm's focus has primarily been on the pharmaceutical sector and medical technology companies. Signet maintains a disciplined, yet flexible investment approach. As an active investor, Signet partners closely with its companies to build their value including facilitating activities between portfolio companies. During Signet's 18-year history, it has developed a strong reputation and track record of successful investments. Signet has raised four funds with total capital commitments of over USD 400 million and has invested in more than 45 companies. More information about Signet Healthcare Partners can be found at . About Bionpharma Bionpharma is a vibrant and fast growing generic pharmaceutical company with a strong commercial portfolio and a pipeline of generic products in the United States. With offices in Princeton, NJ, and Raleigh, North Carolina Bionpharma is one of the largest suppliers of Softgel capsules in the United States with a presence in the prescription and OTC segments of the market. Bionpharma’s focus is on R&D-to develop and commercialize affordable generics through building strong and effective partnerships. More information about Bionpharma Inc. can be found at . Jerry Liao +1 917-865-0528 jerry.liao@signethp.com